NCT01406340View on ClinicalTrials.gov

Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 30, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions

Anaemia

Interventions

DRUG

5 mg GSK1278863

5 mg per day administered orally for 14 days for normal subjects and subjects with Stage 3/4 renal function; 5 mg per day administered orally for 15 days for subjects with Stage 5 renal function

Trial Locations (3)

32809

GSK Investigational Site, Orlando

33169

GSK Investigational Site, Miami

55404

GSK Investigational Site, Minneapolis